DCA
REGN icon

DSG Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

DSG Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-860
Closed -$545K – 131
2025
Q1 		$545K Buy
860
+13
+2% +$8.94K 0.11% 92
2024
Q4 		$603K Buy
+847
New +$711K 0.11% 89

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

DSG Capital Advisors's REGN Position: Q2 2025 in Review

DSG Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 860 shares — an estimated $545K sold.

DSG Capital Advisors first reported a position in REGN in Q4 2024 and held it in 2 quarters. The position peaked at $603K in Q4 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • DSG Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • DSG Capital Advisors sold 860 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $545K.
  • DSG Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • DSG Capital Advisors's Regeneron Pharmaceuticals position peaked at $603K in Q4 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on DSG Capital Advisors's 13F filing for Q2 2025, filed 15 Jul 2025.